natgillin/translations-raw huggingface dataset:
Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Nehotična injekcija/samoinjiciranje može prouzročiti jaku bol i otjecanje, naročito ako se injicira u zglob prsta, a u rijetkim slučajevima može rezultirati gubitkom zahvaćenog prsta ukoliko nije pružena hitna medicinska pomoć.
Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Slučajna injekcija kod ljudi može izazvati jaku bol i oteklinu naročito ako se ubode u zglob prsta, i u rijetkim slučajevima može dovesti do gubitka prsta ako se ne pruži hitna medicinska pomoć.
Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Nehotična injekcija/ samoinjiciranje može prouzročiti jaku bol i oticanje, naročito ako se injicira u zglob prsta, a u rijetkim slučajevima može rezultirati gubitkom zahvaćenog prsta ukoliko nije pružena hitna medicinska pomoć.
Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Nehotična injekcija/samo injiciranje može prouzročiti jaku bol i otjecanje, naročito ako se injicira u zglob prsta, a u rijetkim slučajevima može rezultirati gubitkom zahvaćenog prsta ukoliko nije pružena hitna medicinska pomoć.
Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Nehotična injekcija/samoinjiciranje može prouzročiti jaku bol i otok, naročito ako se injicira u zglob prsta, a u rijetkim slučajevima može rezultirati gubitkom zahvaćenog prsta ukoliko nije pružena hitna medicinska pomoć.
accidental loss or leakage of urine
nehotično ispuštanje mokraće
Accidental one-time exposure to freezing temperatures does not adversely affect the stability of Grastofil.
Nehotično jednokratno izlaganje temperaturama zamrzavanja ne utječe štetno za stabilnost Grastofila.
accidental overdose
slučajno predoziranje
Accidental overdose of enoxararin sodium after intravenous, extracorporeal or subcutaneous administration may lead to haemorrhagic complications.
Nehotično predoziranje enoksaparin-natrijem nakon intravenske, ekstrakorporalne ili supkutane primjene može dovesti do hemoragijskih komplikacija.
Accidental overdose of enoxararin sodium after intravenous, extracorporeal or subcutaneous administration may lead to haemorrhagic complications.
Nehotično predoziranje enoksaparinnatrijem nakon intravenske, ekstrakorporalne ili supkutane primjene može dovesti do hemoragijskih komplikacija.
Accidental overdose of this medicine after intravenous, extracorporeal or subcutaneous administration may lead to haemorrhagic complications.
Nehotično predoziranje ovim lijekom nakon intravenske, vantjelesne ili supkutane primjene može dovesti do komplikacija krvarenja.
Accidental self injection may cause pain.
Nehotično samoinjiciranje može uzrokovati bol.
Accidental self-injection can provoke clinical signs of hypoglycaemia and there is a low possibility of an allergic reaction in sensitised individuals.
Nehotično samoinjiciranje može izazvati kliničke znakove hipoglikemije, a u senzibiliziranih osoba postoji i mala mogućnost za alergijsku reakciju.
Accidental self-injection can provoke clinical signs of hypoglycaemia and there is a low possibility of an allergic reaction in sensitised individuals.
Nehotično samoinjiciranje može izazvati kliničke znakove hipoglikemije, a u senzibiliziranih osoba postoji mala mogućnost alergijske reakcije.
Accidental self-injection is dangerous.
Nehotično injiciranje je opasno.
Accidental self-injection is dangerous.
Nehotično je samoinjiciranje opasno.
Accidental self-injection is dangerous.
Nehotično samoinjiciranje je opasno.
Accidental self-injection is dangerous.
Slučajno samoinjiciranje je opasno.
Accidental self-injection may give rise to pain.
Nehotično samo-injiciranje može uzrokovati bol.
Accidental self-injection may give rise to pain.
Nehotično samoinjiciranja može prouzročiti bol.
Accidental self-injection may result in an inflammatory reaction with severe pain and swelling.
Slučajno samo iniciranje može uzrokovati upalnu reakciju praćenu jakom boli i oteklinom.
Accidentally falling
Nehotično padanje
Accidentally ingestion can be lethal for children.
Nehotično gutanje može biti smrtonosno za djecu.
Accidentally taking too much Lamivudine Teva is unlikely to cause any serious problems.
Mala je vjerojatnost ozbiljnijih problema u bolesnika koji su slučajno uzeli preveliku dozu lijeka Lamivudin Teva.
Accidentally taking too much Lamivudine Teva Pharma B.V. is unlikely to cause any serious problems.
Mala je vjerojatnost ozbiljnijih problema u bolesnika koji su slučajno uzeli preveliku dozu lijeka Lamivudin Teva Pharma B.V.
Accipitriformes (hawks) Strigiformes (owls)
Jastrebovke (jastrebi) Sovke (sove)
Accofil 30 MU/0.5 ml (0.6 mg/ml) solution for injection or infusion in pre-filled syringe filgrastim
Accofil 30 MU/0,5 ml (0,6 mg/ml) otopina za injekciju ili infuziju u napunjenoj štrcaljki filgrastim
Accofil 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Accofil 30 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki
Accofil 30 MU/0.5 ml solution for injection/infusion filgrastim
Accofil 30 MU/0,5 ml otopina za injekciju ili infuziju filgrastim
Accofil 48 MU/0.5 ml (0.96 mg/ml) solution for injection or infusion in pre-filled syringe filgrastim
Accofil 48 MU/0,5 ml (0,96 mg/ml) otopina za injekciju ili infuziju u napunjenoj štrcaljki filgrastim
Accofil 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Accofil 48 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki
Accofil 48 MU/0.5 ml solution for injection/infusion filgrastim
Accofil 48 MU/0,5 ml otopina za injekciju ili infuziju filgrastim
Accofil and neutropenia (low number of a type of white blood cells) associated with chemotherapy
Accofil i neutropenija (nizak broj podvrste bijelih krvnih stanica) uzrokovana kemoterapijom
Accofil contains no preservative.
Accofil ne sadrži konzervanse.
Accofil is a biosimilar medicinal product.
Accofil je bioslični lijek.
Accofil is available in packs containing 1, 3, 5, 7 and 10 pre-filled syringes, with prefixed needle safety guard in individual blister pack or without needle safety guard / blister and alcohol swabs.
Accofil je dostupan u pakiranjima koja sadrže 1, 3, 5, 7 ili 10 napunjenih štrcaljki sa ugrađenim sigurnosnim štitnikom za iglu u pojedinačnom blister pakiranju ili bez sigurnosnog štitnika za iglu / blister i maramicama natopljenim alkoholom.
Accofil is available in packs containing 1, 3, 5, 7 and 10 pre-filled syringes, with prefixed needle safety guard in individual blister pack or without needle safety guard / blister and alcohol swabs.
Accofil je dostupan u pakiranjima koja sadrže 1, 3, 5, 7 ili 10 napunjenih štrcaljki, sa ugrađenim sigurnosnim štitnikom za iglu u pojedinačnom blister pakiranju ili bez sigurnosnog štitnika za iglu / blister i maramicama natopljenim alkoholom.
Accofil must not be diluted with saline solutions.
Accofil se ne smije razrjeđivati pomoću fiziološke otopine.
Accofil should not be diluted with sodium chloride solution.
Accofil se ne smije razrjeđivati s otopinom natrijeva klorida.
Accommodation disorder
poremećaj akomodacije
accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation
praćen porastom direktnog bilirubina, ili praćen kliničkim simptomima oštećenja jetre ili znakovima dekompenzacije jetre.
accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation.
praćen porastom direktnog bilirubina, ili praćen kliničkim simptomima oštećenja jetre ili znakovima dekompenzacije jetre.
Accord Healthcare Limited Sage house, 319, Pinner road North Harrow
Accord Healthcare Limited, Sage house, 319 Pinner Road, North Harrow,
Accord Healthcare Limited Tel : +44 (0)208 863 1427
Accord Healthcare Limited
Accord Healthcare Limited, Sage House, 319 Pinner Road,
Accord Healthcare Limited, Sage House, 319 Pinner road, North Harrow,
Accord Healthcare Limited, Sage house, 319 Pinner Road, Harrow HA1 4HF, United Kingdom Pharmacare Premium Limited, HHF 003, Hal Far Industrial Estate Birzebbugia, BBG 3000, Malta KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Accord Healthcare Limited, Sage house, 319 Pinner Road, Harrow HA1 4HF, Velika Britanija Pharmacare Premium Limited, HHF 003, Hal Far Industrial Estate Birzebbugia, BBG 3000, Malta KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija
Accord Healthcare Limited, Sage house, 319 Pinner road, North Harrow
Accord Healthcare Limited, Sage house, 319 Pinner road, North Harrow,
Accord Healthcare Limited, Sage house, 319 Pinner road, North Harrow
Accord Healthcare Limited, Sage House, 319 Pinner Road, North Harrow, Middlesex HA1 4HF,
Accord Healthcare Limited, Sage House, 319 Pinner Road, North Harrow,
Accord Healthcare Limited, Sage House 319, Pinner Road, North Harrow,
According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment.
Prema ispitivanjima farmakokinetike u bolesnika s karcinomom koji su imali blago do umjereno narušenu funkciju jetre zbog jetrenih metastaza, bioraspoloživost kapecitabina i izloženost 5-FU mogu biti veći u usporedbi s bolesnicima koji nemaju narušenu funkciju jetre.
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:
Sukladno članku 71 Direktive 2001/82/EZ Europskog parlamenta i Vijeća s izmjenama i dopunama, države članice, u skladu s nacionalnim zakonodavstvom mogu zabraniti proizvodnju, uvoz, posjedovanje, prodaju, opskrbu i/ili primjenu imunoloških veterinarsko-medicinskih proizvoda na cijelom ili na dijelu svog teritorija ako je utvrđeno da:
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of their territory if it is established that:
Sukladno članku 71 Direktive 2001/82/EC Europskog Parlamenta i Vijeća države članice zabranjuju ili mogu, u skladu s državnom legislativom zabraniti proizvodnju, uvoz, posjedovanje, prodaju, opskrbu i/ili primjenu imunološkog veterinarsko-medicinskih proizvoda na cijelom teritoriju ili na jednom njegovom dijelu ako je utvrđeno da:
According to clinical response and tolerability, the dose may be increased by 200 mg/day increments, as frequently as every two days, up to a maximum recommended dose of 1000 mg/day (25 ml/day).
Sukladno kliničkom odgovoru i podnošljivosti, doza se može postupno povećavati za 200 mg na dan, najviše svaka dva dana, do maksimalne preporučene doze od 1000 mg na dan (25 ml na dan).
According to clinical response and tolerability, the dose may be increased by 200 mg/day increments, as frequently as every two days, up to a maximum recommended dose of 1000 mg/day.
Sukladno kliničkom odgovoru i podnošljivosti, doza se može postupno povećavati za 200 mg na dan najviše svaka dva dana do maksimalne preporučene doze od 1000 mg na dan.
According to clinical response and tolerability, the dose may be increased by 200 mg/day increments, as frequently as every two days, up to a maximum recommended dose of 1000 mg/day.
Sukladno kliničkom odgovoru i podnošljivosti, doza se može postupno povećavati za 200 mg na dan, najviše svaka dva dana do maksimalne preporučene doze od 1000 mg na dan.
According to clinical response and tolerability, the dose may be increased by 200 mg/day increments, as frequently as every two days, up to a maximum recommended dose of 1000 mg/day.
Sukladno kliničkom odgovoru i podnošljivosti, doza se može postupno povećavati, za 200 mg na dan, najviše svaka dva dana, do maksimalne preporučene doze od 1000 mg na dan.
According to clinical response and tolerability, the dose may be increased by 400 mg/day increments, as frequently as every two days, up to a maximum recommended dose as indicated in the table below.
Sukladno kliničkom odgovoru i podnošljivosti, doza se može povećavati za 400 mg na dan, najviše svaka dva dana, do maksimalne preporučene dnevne doze kako je navedeno u tablici niže.
According to clinical response and tolerability, the dose may be increased by 400 mg/day increments, as frequently as every two days, up to a maximum recommended dose as indicated in the table below.
Sukladno kliničkom odgovoru i podnošljivosti, doza se može povećavati za 400 mg na dan, najviše svaka dva dana, do maksimalne preporučene dnevne doze, kako je navedeno u tablici niže.
According to criteria laid down by the CHMP, a mock-up vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable.
U skladu s kriterijima iznesenim od strane CHMP-a ogledno cjepivo treba potaknuti razvoj zaštitnih razina protutijela kod najmanje 70% osoba da bi se moglo smatrati prikladnim.
According to current guidelines, medicines that have been shown to be effective in patients with PID and in patients with ITP can also be approved for use in the treatment of all types of primary immunodeficiency, as well as low antibody levels due to blood cancers and AIDS in children.
Sukladno aktualnim smjernicama, lijekovi za koje je utvrđeno da su djelotvorni u bolesnika s PID-om i u bolesnika s ITP-om također mogu biti odobreni za primjenu u liječenju svih tipova primarne imunodeficijencije kao i niskih razina protutijela uzrokovanih raznim oblicima raka krvi ili AIDS-om u djece.
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended
Prema trenutnom smjernicama za liječenje, općenito se ne preporučuje dvostruka terapija inhibitorima proteaze
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended.
Prema postojećim smjernicama za liječenje, dvojno liječenje inhibitorima proteaza općenito se ne preporučuje.
According to epidemiological findings, a higher incidence of cardiovascular events has been associated with certain indicators, for instance:
Prema epidemiološkim podacima, veća incidencija kardiovaskularnih događaja povezana je s nekim određenim pokazateljima, na primjer:
According to epidemiological findings, a higher incidence of cardiovascular events has been associated with certain indicators, for instance:
Prema epidemiološkim podacima, veća incidencija kardiovaskularnih događaja povezana je s određenim pokazateljima, na primjer:
According to literature reports, it may be considered that both spermatogenetic and genetic damage in male testis are unlikely at the dose of 1,000 MBq.
Prema izvješćima iz literature, može se smatrati da pri dozi radioaktivnosti od 1.000 MBq vjerojatno neće doći do spermatogenetskog i genetskog oštećenja u testisima muškarca.
According to subgroup analysis in children at 1 to 12 years of age, the incidence of laboratory-confirmed clinical influenza among children was significantly reduced from 19 % (21 / 111) in the group not receiving prevention to 7 % (7 / 104) in the group receiving prevention (64.4 % reduction [95 % CI 15.8 – 85.0; p = 0.0188]).
Prema analizi podskupine djece u dobi od 1 do 12 godina došlo je do znatnog smanjenja incidencije laboratorijski potvrđene klinički izražene gripe: od 19 % (21/111) u skupini u kojoj nije provedena prevencija, na 7 % (7/104) u skupini u kojoj je prevencija provedena (smanjenje od 64,4 % [95 % CI 15,8 – 85,0; p = 0,0188]).
According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum.
Prema sadašnjem shvaćanju, simptomi Parkinsonove bolesti su povezani s pražnjenjem dopamina u corpusu striatumu.
According to the ICH E14 Guideline, this is considered a definitively negative thorough QT/QTc study.
Prema Smjernici ICH E14, to se smatra potpuno negativnim nalazom detaljnog ispitivanja QT/QTc intervala.
According to the Memorial Sloan Kettering Cancer Center criteria for prognostic risk category, 46% were favorable (0 risk factors), 42% were intermediate (1 risk factor), and 13% were poor (2 or 3 risk factors).
Prema Memorial Sloan Kettering Cancer Center (MSKCC) prognostičkim kriterijima, 46 % bolesnika imalo je dobru prognozu (0 rizičnih faktora), 42 % srednju (1 rizični faktor) i 13 % lošu prognozu (2 ili 3 rizična faktora).
According to this daily carbidopa dose, the maximum recommended daily 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Corbilta 200 mg/50 mg/200 mg dose is 7 tablets per day.
Prema ovoj dnevnoj dozi karbidope, najviša preporučena dnevna doza Corbilte 175 mg/43,75 mg/200 mg je 8 tableta na dan, a Corbilte 200 mg/50 mg/200 mg je 7 tableta na dan.
According to this daily carbidopa dose, the maximum recommended daily Corbilta 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Corbilta 200 mg/50 mg/200 mg dose is 7 tablets per day.
Prema ovoj dnevnoj dozi karbidope, najviša preporučena dnevna doza Corbilte 175 mg/43,75 mg/200 mg je 8 tableta na dan, a Corbilte 200 mg/50 mg/200 mg je 7 tableta na dan.
According to this daily carbidopa dose, the maximum recommended daily Stalevo 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Stalevo 200 mg/50 mg/200 mg dose is 7 tablets per day.
Prema ovoj dnevnoj dozi karbidope, najviša preporučena dnevna doza Staleva 175 mg/43,75 mg/200 mg je 8 tableta na dan, a Staleva 200 mg/50 mg/200 mg je 7 tableta na dan.
According to your response, your doctor may decide to add every day a dose of follitropin alfa to your Pergoveris injection.
Ovisno o Vašem odgovoru na lijek, liječnik Vam može povećati dnevnu dozu folitropina alfa u injekciji lijeka Pergoveris.
According to your response, your doctor may increase your dose of FSH by preferably 37.5-75 IU at 7 to 14-day intervals.
U skladu s Vašim odgovorom, liječnik može povećati dozu FSH po mogućnosti za 37,5 do 75 IU u razmacima od 7 do 14 dana.
According to your response, your doctor may increase your dose of FSH by preferably 37.5-75 IU at 7 to 14-day intervals.
U skladu s Vašim odgovorom, Vaš liječnik može povećati Vašu dozu FSH po mogućnosti za 37,5 do 75 IU u razmacima od 7 do 14 dana.
Accordingly, a risk of migalastat exposure to the breast- feeding infant cannot be excluded.
U skladu s tim, ne može se isključiti rizik od izloženosti migalastatu u dojenčeta.
Accordingly, as anaemia, granulocytopenia, anaphylactic reaction, jaundice, Stevens-Johnson Syndrome/toxic epidermal necrolysis (which may be fatal), angioedema, decreased blood phosphorus and increased blood pressure during maintenance phase with Viramune prolonged-release tablets were not seen in study 1100.1486 the frequency category was estimated from a statistical calculation based on the total number of patients exposed to nevirapine prolonged-release in the maintenance phase of the randomised controlled clinical study 1100.1486 (n= 505).
Shodno tome, s obzirom da anemija, granulocitopenija, anafilaktička reakcija, žutica, Stevens- Johnsonov sindrom/toksična epidermalna nekroliza (može biti fatalna), angioedem, snižene vrijednosti fosfora u krvi i povišeni krvni tlak nisu viđeni tijekom razdoblja održavanja Viramune tabletama s produljenim oslobađanjem u ispitivanju 1100.1486, kategorija učestalosti procijenjena je iz statističkog izračuna na osnovi ukupnog broja bolesnika izloženih nevirapinu s produljenim oslobađanjem u razdoblju održavanja randomiziranog kontroliranog kliničkog ispitivanja 1100.1486 (n= 505).
Accordingly, healthcare professionals should employ appropriate precautions when handling leukapheresis material or Provenge (see section 4.4).
Prema tome, zdravstveni djelatnici se trebaju pridržavati odgovarajućih mjera opreza prilikom rukovanja uzorkom dobivenim leukaferezom ili lijekom Provenge (vidjeti dio 4.4).
Accordingly, healthcare professionals should employ appropriate precautions when handling the leukapheresis material or Provenge.
Prema tome, zdravstveni djelatnici se trebaju pridržavati odgovarajućih mjera opreza prilikom rukovanja uzorkom dobivenim leukaferezom ili lijekom Provenge.
Accordingly, high-risk patients, particularly young children and those receiving substantial immunosuppression should be monitored, using such procedures as echocardiography or ECG pre- and post-transplant (e.g. initially at 3 months and then at 9-12 months).
Sukladno tome, potrebno je nadzirati visokorizične bolesnike, osobito malu djecu i one koji primaju znatnu imunosupresijsku terapiju pomoću postupaka kao što je ehokardiografija ili elektrokardiografija prije i poslije transplantacije (npr. u početku nakon 3 mjeseca, a zatim nakon 9- 12 mjeseci).
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol.
Sukladno tome, u ispitivanjima in vivo nisu opažene klinički značajne farmakokinetičke interakcije između pregabalina i fenitoina, karbamazepina, valproične kiseline, lamotrigina, gabapentina, lorazepama, oksikodona ili etanola.
Accordingly, longer infusion times should be considered in children weighing  20 kg (see section 4.2).
U skladu s time treba razmotriti uvođenje duljeg trajanja infuzije u djece težine  20 kg (vidjeti dio 4.2).
Accordingly, patients should be advised not to drive a car or to operate other potentially hazardous machinery until they are familiar with the effects of lacosamide on their ability to perform such activities.
U skladu s tim bolesnike treba savjetovati da ne upravljaju vozilima ili drugim potencijalno opasnim strojevima dok se ne upoznaju s učincima lakozamida na njihovu sposobnost obavljanja takvih aktivnosti.
Accumulation at the site of respiratory tract infection is demonstrated by high and sustained tildipirosin concentrations in lung and bronchial fluid (collected post mortem), which far exceed those in blood plasma.
Akumulacija na mjestu infekcije dišnog sustava je dokazana uvisokom i trajnom koncentracijom tildipirosina u plućima i bronhalnoj tekućini (skupljeno post mortem), što daleko premašuje onu u krvnoj plazmi.
Accumulation at the site of respiratory tract infection is demonstrated by high and sustained tildipirosin concentrations in lung and bronchial fluid, which far exceed those in blood plasma.
Akumulacija na mjestu infekcije dišnog sustava je dokazana visokom i trajnom koncentracijom tildipirosina u plućima i bronhalnoj tekućini (skupljeno post mortem), što daleko premašuje onu u krvnoj plazmi.
Accumulation cannot be discounted in adult dogs.
Akumulacija se ne može isključiti kod odraslih pasa.
accumulation of blood in the front part of the eye
nakupljanje krvi u prednjem dijelu oka
accumulation of fat in the liver
nakupljanje masnoće u jetri
accumulation of fluid (oedema)
nakupljanje tekućine (edem)
Accumulation of fluid and air in the stomach (abdomen) or lung after surgery (pleural effusion, abdominal distension, ascites, pancreatic fluid collection).
Nakupljanje tekućine i zraka u želucu (trbuhu) ili plućima nakon kirurškog zahvata (pleuralni izljev, rastezanje trbuha, ascites, nakupljanje tekućine oko gušterače).